VTYX

Company Overview — What Does Ventyx Biosciences, Inc. Do?

Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis, inflammatory bowel disease, psoriatic arthritis, Crohn's disease, and lupus. It also develops VTX002, an oral sphingosine 1 phosphate receptor 1 modulator that is in phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 (NLRP3) inflammasome inhibitor for the treatment of systemic inflammatory diseases, such as cardiovascular, hepatic, renal, and rheumatologic diseases which is in phase I clinical trials. In addition, the company develops CNS-penetrant NLRP3 inhibitors for the treatment of Alzheimer disease, Parkinson disease, amyotrophic lateral sclerosis, and multiple sclerosis. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in Encinitas, California. Ventyx Biosciences, Inc. (VTYX) is classified as a small-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Raju S. Mohan and employs approximately 30 people. With a market capitalization of $1.0B, VTYX is one of the notable companies in the Healthcare sector.

Ventyx Biosciences, Inc. (VTYX) Stock Rating — Hold (April 2026)

As of April 2026, Ventyx Biosciences, Inc. receives a Hold rating with a composite score of 42.4/100 and 3 out of 5 stars from the Blank Capital Research quantitative model.VTYX ranks #1,014 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Ventyx Biosciences, Inc. ranks #72 of 838 stocks, placing it in the top 10% of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

VTYX Stock Price and 52-Week Range

Ventyx Biosciences, Inc. (VTYX) currently trades at $14.00. The stock gained $0.03 (0.2%) in the most recent trading session. The 52-week high for VTYX is $25.00, which means the stock is currently trading -44.0% from its annual peak. The 52-week low is $0.78, putting the stock 1688.0% above its annual trough. Recent trading volume was 5.4M shares, reflecting moderate market activity.

Is VTYX Overvalued or Undervalued? — Valuation Analysis

Ventyx Biosciences, Inc. (VTYX) carries a value factor score of 31/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 5.25x, versus the sector average of 2.75x.

At current multiples, Ventyx Biosciences, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Ventyx Biosciences, Inc. Profitability — ROE, Margins, and Quality Score

Ventyx Biosciences, Inc. (VTYX) earns a quality factor score of 26/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -58.8%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -53.2% versus the sector average of -33.1%.

Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

VTYX Debt, Balance Sheet, and Financial Health

Ventyx Biosciences, Inc. has a debt-to-equity ratio of 11.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 17.86x, indicating strong short-term liquidity. Total debt on the balance sheet is $0. Cash and equivalents stand at $32M.

VTYX has a beta of 1.33, meaning it is more volatile than the broader market — a $10,000 investment in VTYX would be expected to move 33.5% more than the S&P 500 on any given day. The stability factor score for Ventyx Biosciences, Inc. is 34/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Ventyx Biosciences, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Ventyx Biosciences, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.32. Net income for the quarter was $-113M. Operating income came in at $-123M.

In Q3 2025, Ventyx Biosciences, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.32. Net income for the quarter was $-23M. Operating income came in at $-25M.

In Q2 2025, Ventyx Biosciences, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.38. Net income for the quarter was $-27M. Operating income came in at $-29M.

In Q1 2025, Ventyx Biosciences, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.39. Net income for the quarter was $-27M. Operating income came in at $-30M.

Over the past 8 quarters, Ventyx Biosciences, Inc. has experienced revenue contraction from $0 to $0. Investors analyzing VTYX stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

VTYX Dividend Yield and Income Analysis

Ventyx Biosciences, Inc. (VTYX) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

VTYX Momentum and Technical Analysis Profile

Ventyx Biosciences, Inc. (VTYX) has a momentum factor score of 79/100, indicating strong price momentum with the stock outperforming the majority of the market over recent periods. Stocks with high momentum scores have historically tended to continue their outperformance in the near term. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 43/100 reflects moderate short selling activity.

VTYX vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Ventyx Biosciences, Inc. (VTYX) ranks #72 out of 838 stocks based on the Blank Capital composite score. This places VTYX in the top decile of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing VTYX against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full VTYX vs S&P 500 (SPY) comparison to assess how Ventyx Biosciences, Inc. stacks up against the broader market across all factor dimensions.

VTYX Next Earnings Date

No upcoming earnings date has been announced for Ventyx Biosciences, Inc. (VTYX) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy VTYX? — Investment Thesis Summary

Ventyx Biosciences, Inc. presents a balanced picture with arguments on both sides. The quality score of 26/100 flags below-average profitability. The value score of 31/100 indicates premium valuation. Price momentum is positive at 79/100, suggesting the trend favors buyers. High volatility (stability score 34/100) increases portfolio risk.

In summary, Ventyx Biosciences, Inc. (VTYX) earns a Hold rating with a composite score of 42.4/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on VTYX stock.

Related Resources for VTYX Investors

Explore more research and tools: VTYX vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare VTYX head-to-head with peers: VTYX vs AZN, VTYX vs SLGL, VTYX vs VMD.